CDC/ACIP [to 30 Mar 2019]

CDC/ACIP [to 30 Mar 2019]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

Latest News
CDC: Artesunate Now First-Line Treatment for Severe Malaria in the United States
Thursday, March 28, 2019
Only FDA-approved antimalarial drug, quinidine, has been discontinued

Ebola outbreak in eastern Democratic Republic of Congo tops 1,000 cases
Monday, March 25, 2019
CDC remains committed to bringing outbreak to an end
As of March 24, 2019, public health officials have documented that the Ebola outbreak in eastern Democratic Republic of Congo (DRC) has surpassed 1,000 cases; the current total number of confirmed and probable cases is 1009, including 625 deaths and 318 survivors. The outbreak is the largest in DRC’s history and the second largest outbreak recorded of Ebola ever (after the 2014-2016 outbreak in West Africa).
“This is a disappointing milestone. This remains a highly complex Ebola outbreak with active transmission in 13 of the 21 affected health zones,” said CDC Director Robert R. Redfield, M.D. “Despite this, CDC will continue to work 24/7 with our partners in DRC, in DRC’s neighboring countries, and around the world to prevent the spread of Ebola and bring this outbreak to an end.”…

MMWR News Synopsis for Friday, March 29, 2019
Enterovirus D68-Associated Acute Respiratory Illness — United States, July–October, 2017 and 2018
CDC recently established surveillance of children seen in emergency departments or hospitalized for acute respiratory illness at seven U.S. medical centers. Substantially more children tested positive for Enterovirus D68 (EV-D68) in the 2018 season compared with 2017.
EV-D68 is one of many known enteroviruses. It can cause mild to severe respiratory illness or no symptoms at all. EV-D68 infections typically peak during late summer and early fall in the United States. National reporting of EV-D68 is voluntary. To better understand annual trends of EV-D68 illness, seven U.S. medical centers, participating in CDC’s New Vaccine Surveillance Network (NVSN), are conducting surveillance among children either seen in emergency departments or hospitalized for acute respiratory illness (ARI). From July 1 – October 31, 2018, EV-D68 infections were detected in 358 children with ARI, compared with two during the same period in 2017. Continued active surveillance of EV-D68-associated ARI is key to understanding the circulation and seasonality of EV-D68.

Africa CDC   [to 30 Mar 2019]

Africa CDC   [to 30 Mar 2019]
https://au.int/en/africacdc
March 29, 2018
First Progress Report of the Chairperson of the Commission on the Africa Center for Disease Control
11 pages – PDF: https://au.int/sites/default/files/documents/34074-doc-auc.report.africa.cdc_.prc_.29.03.pdf
[Excerpt]
… 22. At this time, Africa CDC’s fulfilment of its mandate is hampered by small numbers of permanent staff supporting administrative functions at the secretariat. The majority of Africa CDC support currently comes from seconded or contracted staff. Efforts are underway to address these challenges.

23. Africa CDC has succeeded in developing bilateral partnerships with several nations outside the African continent. Within AU Member States, only the Republic of Kenya has provided a voluntary contribution of USD 1 million to support the Africa CDC. Sustainable support among Member States is critical for sustainable growth and expansion of Africa CDC.

24. Africa CDC is pursuing a mechanism for sustainable financing through businesses, the private sector, and African philanthropy. The Africa CDC private sector and philanthropy engagement strategy has been developed and presented to the Africa CDC Governing Board. This strategy has been aligned and coordinated with plans for Africa CDC Foundation. A priority
focus has been on identifying African companies dealing in telecommunications and other sectors. Finally, Africa CDC is engaging African philanthropists who have given historical support to the African health agenda.

V. OBSERVATIONS
25. Africa CDC has recorded notable achievements to mark its first year of existence. It is successfully fulfilling the mandate it received from the Assembly, even while it continually expands and develops new avenues for strengthening public health capacity on the African continent.

26. Member States have demonstrated their continued support and enthusiasm for Africa CDC by robust participation to produce various framework documents that will guide their public health activities at the national level. These framework documents include a strategy to introduce event-based surveillance at the continental, regional, and national levels; a framework to establish a national public health institute in every Member State; a framework
to address the threat of antimicrobial resistance.

27. In its inaugural year, Africa CDC responded to ten public health events in Member States with a limited technical staff (only ten epidemiologists are currently seconded to Africa CDC). These same epidemiologists also provide day-to-day administrative and management support to operations at the Africa CDC secretariat.

28. While three of the Africa CDC RCC have had successful political launches, they require substantial human resource support to ensure that the technical aspects of Africa CDC’s strategic plan is successfully implemented at the regional level. Without each RCC, Africa CDC has limited ability to encourage public health coordination among Member States. It is crucial to ensure that the West Africa and North Africa are launched in 2018. I look forward to nominating a North African technical public health institution motivated and equipped to provide support to the entire region, cognizant of the diverse array of needs represented in North Africa.

29. I encourage Member States to participate actively in the public health platform established by the Regional Collaborating Centres. Laboratory networks, coordination during public health events, and information exchange are critical elements of the RCC mandate.
End

Announcements

Announcements

 

Paul G. Allen Frontiers Group    [to 30 Mar 2019]
https://www.alleninstitute.org/news-press/
No new digest content identified.
 
 
BMGF – Gates Foundation  [to 30 Mar 2019]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.
 
 
Bill & Melinda Gates Medical Research Institute    [to 30 Mar 2019]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
 
 
CARB-X   [to 30 Mar 2019]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.
 
 
CEPI – Coalition for Epidemic Preparedness Innovations  [to 30 Mar 2019]
http://cepi.net/
29 Mar 2019
The woman who helped to stop an Ebola epidemic in Nigeria
By Niniola Soleye
In 2014-2016, West Africa experienced the largest Ebola outbreak to date. Thanks to the heroic work of Dr Ameyo Stella Adadevoh and others, Nigeria steered clear of what could have been a very deadly outbreak of the disease. Tragically Dr Adadevoh lost her life to Ebola, but her legacy lives on today through the Dr Ameyo Stella Adadevoh Health Trust…

29 Mar 2019 – Comment
You can’t beat epidemics without equitable access to vaccines
By Richard Hatchett, CEPI CEO
We’re developing vaccines against emerging infectious diseases. Getting them to the people who need them, when they need them, regardless of ability to pay, is not just important for access, it’s the only way to beat epidemic… CEPI is 100% committed to equitable access. This commitment drives every aspect of our work and is key to our success as a global health organisation…
 
 
EDCTP [to 30 Mar 2019]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.
 
 
Emory Vaccine Center [to 30 Mar 2019]
http://www.vaccines.emory.edu/
No new digest content identified.
 
 
European Medicines Agency  [to 30 Mar 2019]
http://www.ema.europa.eu/ema/
News and press releases
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 March 2019
CHMP, 29/03/2019
 
 
European Vaccine Initiative  [to 30 Mar 2019]
http://www.euvaccine.eu/news-events
Latest news
GHIT supports further development of a new asexual blood-stage malaria vaccine candidate
29 March 2019
Goal of new project is to further advance the development of a new vaccine candidate based on the PfRipr5 protein of…
 
 
FDA [to 30 Mar 2019]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
March 29, 2019 –
Statement by FDA Commissioner Scott Gottlieb, M.D., Director of FDA’s Center for Drug Evaluation and Research Janet Woodcock, M.D. and Director of FDA’s Center for Biologics Evaluation and Research Peter Marks, M.D. on Expanded Access –Looking Forward
…But sometimes, even in circumstances where the availability of a medicine through EA would appropriately balance these considerations, such access is not available. This is often true when it comes to the ability of patients to continue to use a promising medicine after the completion of a clinical trial.
We are writing to encourage sponsors to offer EA in such circumstances, when continued access to a promising medicine at the completion of a clinical trial would be appropriate under the EA programs.
Although we often focus on EA as providing access to patients who cannot enter clinical trials, EA can also be considered as a mechanism for those who have participated in a trial in order to allow them to continue receiving a drug that may have provided benefit. At the end of a trial, sponsors may continue to provide treatment to participating patients through an extension study to gather additional rigorous information that’s needed to support the subsequent marketing application. Alternatively, if the purpose is primarily to provide the drug to patients who continue to need it, an EA program may be used for either moderately sized populations (intermediate EA) or large size populations (treatment EA), often when most studies in support of approval have been completed. As another option, a sponsor could authorize a patient’s own physician to obtain a single patient EA investigational new drug (IND) application…
 
 

Fondation Merieux [to 30 Mar 2019]
http://www.fondation-merieux.org/
No new digest content identified.

 
Gavi [to 30 Mar 2019]
https://www.gavi.org/
Latest News
27 March 2019
Leadership training for supply chain managers expands to five African countries
Over 22 private sector partners will support the innovative training and mentorship programme.
Nairobi/Accra,– The Strategic Training Executive Programme (STEP) for supply chain managers is expanding to five African countries, including Kenya, Ghana, Mozambique, Madagascar and the Democratic Republic of the Congo (DRC), thanks to financial and in-kind support from the International Federation of Pharmaceutical Wholesalers (IFPW). The expansion of STEP is the result of significant country demand for stronger capacity in supply chain management. By the end of 2020, Gavi and IFPW expect more than 600 immunisation supply chain leaders to graduate from STEP programmes across Africa and Asia.
“STEP has become an essential component of Gavi’s support to strengthen supply chain management in low-income countries,” said Gavi Deputy CEO Anuradha Gupta. “With country demand increasing, what began as an effort to foster regional supply chain expertise in East Africa has extended well beyond this goal. Our continued partnership with IFPW allows even more Gavi-supported countries to benefit from improved management of health supply chains,” she added…
 
 
GHIT Fund   [to 30 Mar 2019]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical

March 28, 2019
GHIT Fund Announces Appointment of Catherine Ohura as New CEO and Executive Director
The Global Health Innovative Technology Fund (GHIT) today announced the appointment of Catherine Ohura as the organization’s new CEO and Executive Director. Ohura brings depth and breadth of expertise and invaluable experience working for R&D and Commercial functions. In the R&D function, Ohura worked in clinical operations, regulatory affairs, quality assurance, project management, finance/resource management, portfolio management, and governance creation/management…

March 28, 2019
GHIT Fund Announces New Investments: A Total of 2.86 Billion Yen in Drug for Schistosomiasis, Dengue, Malaria and Tuberculosis, Vaccines for Leishmaniasis and Malaria, and Diagnostics for Tuberculosis
The Global Health Innovative Technology (GHIT) Fund announced today a total of 2.86 billion yen (US$25.8 million*) to support 10 partnerships to develop new lifesaving drugs, vaccines, and diagnostics for malaria, tuberculosis, dengue, leishmaniasis, and schistosomiasis. This includes three new projects and seven that will receive continued funding. (Appendix 1)
“We are thrilled to see our portfolio continue to advance and accelerate, to expand and evolve. This marks now a total of 17 billion yen (US$153 million*) invested in over 80 global product development partnerships aimed to leverage Japanese science and pharmaceutical capabilities through global partnership. Side by side with our partners, GHIT continues to drive ahead looking to deliver lifesaving tools to save millions of lives.” said, said BT Slingsby, the CEO of GHIT.
Currently, there are 50 ongoing projects including 27 discovery, 15 preclinical, and eight clinical trials in the GHIT portfolio…

Global Fund [to 30 Mar 2019]
https://www.theglobalfund.org/en/news/
News
No new digest content identified.

Hilleman Laboratories [to 30 Mar 2019]
http://www.hillemanlabs.org/
No new digest content identified.

Human Vaccines Project [to 30 Mar 2019]
http://www.humanvaccinesproject.org/media/press-releases/
No new digest content identified.

IAVI  [to 30 Mar 2019]
https://www.iavi.org/newsroom
March 27, 2019
IAVI Announces First-in-Human Clinical Trial of Native-like HIV Envelope Vaccine Candidate
NEW YORK — MARCH 27, 2019 — The International AIDS Vaccine Initiative (IAVI) announced the start of a Phase I clinical trial (IAVI W001) to test a novel HIV vaccine candidate, BG505 SOSIP.664 gp140. The aim of the trial is to assess the safety of the candidate and to determine if vaccination induces the human immune system to produce proteins known as neutralizing antibodies (NAbs).
Mark Feinberg, M.D., Ph.D., president and CEO of IAVI, said, “This trial is unique because it represents the fruition of decades of scientific research to engineer this promising vaccine candidate. Much important work was done in the late 1990s and early 2000s to attempt to stabilize the HIV envelope protein in its native configuration, but this difficult work took several more years to achieve.”
BG505 SOSIP.664 gp140 is based on the HIV envelope protein (Env), which is shaped like a three-pronged spike. This configuration, known as a trimer, is a target for antibodies produced by the human immune system after infection. Some of these antibodies are able to block viral entry into cells.
The BG505 SOSIP.664 gp140 trimer was engineered by a team directed by John P. Moore, Ph.D., at the Weill Cornell Medical College, Rogier Sanders, Ph.D., now at the University of Amsterdam Academic Medical Center, and Andrew B. Ward, Ph.D., and Ian A. Wilson, D.Phil., at Scripps Research. The outcome of their work was an important advance in stabilizing the highly fragile Env protein in a native-like configuration.
This is one of the first clinical trials of a native-like Env trimer, and the first time that this particular trimer is being evaluated in humans…

IFFIm
http://www.iffim.org/library/news/press-releases/
No new digest content identified.

IFRC   [to 30 Mar 2019]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
Americas, Venezuela
IFRC to bring humanitarian aid into Venezuela
The President of the International Federation of Red Cross and Red Crescent Societies (IFRC) has announced that IFRC will have unhindered access to bring humanitarian aid into Venezuela to support a major scale up of medical care and other assistance by the Venezuela Red Cross.
29 March 2019

Afghanistan, Asia Pacific
Afghanistan: Ten million Afghans face severe hardship after extreme weather
Ten million people in Afghanistan – more than a quarter of its population – face severe acute food insecurity and need urgent help after floods and drought, say the Afghan Red Crescent Society and the International Federation of Red Cross and Red Crescent Societies (IFRC).
28 March 2019

Africa, Mozambique
Mozambique: Red Cross races to stop new disaster following confirmation of first cholera cases
News that the first cases of deadly cholera have been confirmed in Mozambique has accelerated Red Cross and Red Crescent disease prevention activities in the vulnerable communities that have been devastated by Cyclone Idai. Jamie LeSueur, head of operations with the International Federation of Red Cross and Red Crescent Societies (IFRC) in Beira, said: “We will all have to move extremely fast to stop these isolated cases from becoming another major disaster within the ongoing crisis of Cyclone Idai.
27 March 2019

Mozambique
Mozambique: “Speed, quality and scale of response critical to preventing disease outbreaks,” says IFRC Secretary General
Geneva/Nairobi/Beira, 25 March 2019 – The Red Cross and Red Crescent network is speeding up efforts to prevent disease outbreaks in the aftermath of Cyclone Idai, with the arrival today of an Emergency Response Unit that will provide sanitation for 20,000 people every day. Two emergency field hospitals will follow. “After a disaster of this magnitude, the speed, quality, and scale of our response is critical to to stop the risk of waterborne disease outbreaks like cholera,” said the Secretary General of the International Federation of Red Cross and Red Crescent Societies (IFRC), Elhadj As Sy, at a media briefing at the United Nations in Geneva today. “As flood waters recede, hundreds of thousands of people still lack water, shelter and health care. We now see even more clearly the real consequences of this disaster.”
25 March 2019

Asia Pacific, Indonesia
Indonesia: Six months after Sulawesi triple disaster, survivors face slow and complex recovery
Palu/Kuala Lumpur, 25 March 2019 – Six months after Sulawesi was hit by a powerful and shallow earthquake, tsunami and liquefaction, survivors face a painfully slow and complex recovery. On 28 September 2018, a series of strong earthquakes struck Centr …
25 March 2019
 
 
IVAC [to 30 Mar 2019]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
No new digest content identified.

IVI [to 30 Mar 2019]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.

JEE Alliance [to 30 Mar 2019]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

 
MSF/Médecins Sans Frontières  [to 30 Mar 2019]
http://www.msf.org/
Selected News; Project Updates, Reports [as presented on website]
Cyclone Idai & Southern Africa flooding
The first six days after Cyclone Idai in Zimbabwe
Voices from the Field 29 Mar 2019

Cyclone Idai & Southern Africa flooding
Malawi: “This time, the flooding has destroyed houses, not lives”
Voices from the Field 29 Mar 2019

Cyclone Idai & Southern Africa flooding
MSF emergency response to Cyclone Idai and flooding
Crisis Update 29 Mar 2019

Palestine
March of Return protestors abandoned after year of suffering
Project Update 28 Mar 2019

Cyclone Idai & Southern Africa flooding
Mozambique declares cholera cases in Beira in wake of Cyclone Idai
Project Update 28 Mar 2019

Cyclone Idai & Southern Africa flooding
Mozambique flooding and response: both enormous in scale
Project Update 27 Mar 2019

Venezuela
MSF’s work across Venezuela
Interview 27 Mar 2019

Yemen
MSF treats exponential increase in cholera cases since start of 2…
Press Release 27 Mar 2019

Central American Migration
People fleeing put at risk through dangerous government migrati…
Voices from the Field 26 Mar 2019

Iraq
The aftermath of the conflict in Hawija: “My only hope is to get b…
Project Update 26 Mar 2019

DRC 2018 Ebola outbreaks
Crisis update – March 2019
Crisis Update 25 Mar 2019
 
 
NIH  [to 30 Mar 2019]
http://www.nih.gov/news-events/news-releases
March 28, 2019
Harnessing T-cell “stemness” could enhance cancer immunotherapy
— Study sheds light on one way tumors may continue to grow despite the presence of cancer-killing immune cells.
 
 
PATH [to 30 Mar 2019]
https://www.path.org/media-center/
No new digest content identified.
 
 
Sabin Vaccine Institute [to 30 Mar 2019]
http://www.sabin.org/updates/pressreleases
No new digest content identified.
 
 
UNAIDS [to 30 Mar 2019]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements

27 March 2019
Liberia’s catch-up plan takes shape

27 March 2019
UN and AU working together for sustainable development

26 March 2019
Modelling the next set of HIV data

25 March 2019
Only half of HIV-exposed babies are tested for HIV
 
 
UNICEF  [to 30 Mar 2019]
https://www.unicef.org/media/press-releases
Selected Press Releases/Reports/Statements

Press release
Participation in sport can improve children’s learning and skills development, new Barça Foundation and UNICEF report finds
The report launches today at an international consultation on sport for development for children at the FC Barcelona Auditorium
28/03/2019

Press release
Cyclone Idai: More than 1.5 million children urgently need assistance across Mozambique, Malawi and Zimbabwe – UNICEF
UN children’s agency launches US$122 million humanitarian appeal amidst worst disaster to hit southern Africa in decades
27/03/2019

Statement
Two years since world’s largest outbreak of Acute Watery Diarrhea and Cholera, Yemen witnessing another sharp increase in reported cases with number of deaths continuing to increase
Statement by Geert Cappelaere, UNICEF Regional Director in the Middle East and North Africa and Dr Ahmed Al Mandhari, WHO Regional Director for the Eastern Mediterranean
26/03/2019

Press release
Participation in sport can improve children’s learning and skills development, new Barça Foundation and UNICEF report finds26/03/2019

Press release
Participation in sport can improve children’s learning and skills development, new Barça Foundation and UNICEF report finds26/03/2019

Press release
Participation in sport can improve children’s learning and skills development, new Barça Foundation and UNICEF report finds26/03/2019

Statement
Statement by UNICEF Executive Director Henrietta Fore on village attack in Mali
24/03/2019

Press release
Participation in sport can improve children’s learning and skills development, new Barça Foundation and UNICEF report findsUNICEF Executive Director Henrietta Fore wraps up visit to affected area of Beira one week after Cyclone hit
23/03/2019
 
 
Vaccine Confidence Project  [to 30 Mar 2019]
http://www.vaccineconfidence.org/
No new digest content identified.
 
Vaccine Education Center – Children’s Hospital of Philadelphia  [to 30 Mar 2019]
http://www.chop.edu/centers-programs/vaccine-education-center
March 2019
Newsletter
Announcements: Webinar update and reminder, autism Q&A revised, vaccine safety issues 
 
 
Wellcome Trust  [to 30 Mar 2019]
https://wellcome.ac.uk/news
Opinion | 29 March 2019
We want to champion new conversations with the public about health
by Lucy McDowell
Wellcome wants to promote new practices in public dialogue to involve a broader, more diverse range of people in discussions about health challenges and how we face them

The Wistar Institute [to 30 Mar 2019]
https://www.wistar.org/news/press-releases
No new digest content identified.

World Organisation for Animal Health (OIE) [to 30 Mar 2019]
http://www.oie.int/en/for-the-media/press-releases/2019/
No new digest content identified.

::::::

BIO [to 30 Mar 2019]
https://www.bio.org/insights/press-release
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 30 Mar 2019]
http://www.dcvmn.org/
No new digest content identified.

IFPMA [to 30 Mar 2019]
http://www.ifpma.org/resources/news-releases/
No new digest content identified.

PhRMA [to 30 Mar 2019]
http://www.phrma.org/press-room
No new digest content identified.

Journal Watch

 

Journal Watch

   Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Infection control influence of Middle East respiratory syndrome coronavirus: A hospital-based analysis

American Journal of Infection Control
April 2019 Volume 47, Issue 4, p351-478
http://www.ajicjournal.org/current

Major Articles
Infection control influence of Middle East respiratory syndrome coronavirus: A hospital-based analysis
Jaffar A. Al-Tawfiq, Rana Abdrabalnabi, Alla Taher, Shantymole Mathew, Kamal Abdul Rahman
p431–434
Published online: November 27, 2018

Understanding influenza vaccination rates and reasons for refusal in caregivers and household contacts of cancer patients

American Journal of Infection Control
April 2019 Volume 47, Issue 4, p351-478
http://www.ajicjournal.org/current

Brief Reports
Understanding influenza vaccination rates and reasons for refusal in caregivers and household contacts of cancer patients
Stephanie A. Price, Sara Podczervinski, Kim MacLeod, Lois Helbert, Steven A. Pergam
p468–470
Published online: December 4, 2018